Logo

Tekmira Receives Milestone from Monsanto

Jul 10, 2014
Premium

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals this week announced that it has received a $1.5 million milestone payment from ag-bio firm Monsanto under the terms of a technology-licensing deal.

Earlier this year, Monsanto signed a four-year deal picking up access to Tekmira's proprietary lipid-based RNAi delivery technology for use in agricultural applications. Shortly after the arrangement was announced, Tekmira received a $14.5 million milestone.

According to Tekmira, the latest payment was triggered by the achievement of undisclosed program developments.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Monsanto
Tekmira
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.